 Imidazoles
"Imidazoles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds containing 1,3-diazole, a five membered aromatic ring containing two nitrogen atoms separated by one of the carbons. Chemically reduced ones include IMIDAZOLINES and IMIDAZOLIDINES. Distinguish from 1,2-diazole (PYRAZOLES).
| Descriptor ID |
D007093
|
| MeSH Number(s) |
D03.383.129.308
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Imidazoles".
Below are MeSH descriptors whose meaning is more specific than "Imidazoles".
This graph shows the total number of publications written about "Imidazoles" by people in this website by year, and whether "Imidazoles" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1992 | 0 | 1 | 1 | | 1993 | 0 | 1 | 1 | | 1995 | 0 | 1 | 1 | | 1996 | 2 | 0 | 2 | | 1997 | 0 | 4 | 4 | | 1998 | 0 | 5 | 5 | | 1999 | 1 | 3 | 4 | | 2000 | 4 | 3 | 7 | | 2001 | 2 | 6 | 8 | | 2002 | 3 | 8 | 11 | | 2003 | 3 | 5 | 8 | | 2004 | 0 | 2 | 2 | | 2005 | 4 | 3 | 7 | | 2006 | 4 | 2 | 6 | | 2007 | 2 | 0 | 2 | | 2008 | 1 | 4 | 5 | | 2009 | 4 | 2 | 6 | | 2010 | 3 | 6 | 9 | | 2011 | 2 | 3 | 5 | | 2012 | 3 | 4 | 7 | | 2013 | 5 | 5 | 10 | | 2014 | 3 | 6 | 9 | | 2015 | 6 | 9 | 15 | | 2016 | 2 | 3 | 5 | | 2017 | 4 | 3 | 7 | | 2018 | 4 | 2 | 6 | | 2019 | 3 | 1 | 4 | | 2020 | 3 | 3 | 6 | | 2021 | 0 | 5 | 5 | | 2022 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Imidazoles" by people in Profiles.
-
Priestley ES, Banville J, Deon D, Dubé L, Gagnon M, Guy J, Lapointe P, Lavallée JF, Martel A, Plamondon S, Rémillard R, Ruediger E, Tremblay F, Posy SL, Guarino VR, Richter JM, Li J, Gupta A, Vetrichelvan M, Balapragalathan TJ, Mathur A, Hua J, Callejo M, Guay J, Sum CS, Cvijic ME, Watson C, Wong P, Yang J, Bouvier M, Gordon DA, Wexler RR, Marinier A. Discovery of Two Novel Antiplatelet Clinical Candidates (BMS-986120 and BMS-986141) That Antagonize Protease-Activated Receptor 4. J Med Chem. 2022 07 14; 65(13):8843-8854.
-
Krop IE, Jegede OA, Grilley-Olson JE, Lauring JD, Mitchell EP, Zwiebel JA, Gray RJ, Wang V, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Kono SA, Ford JM, Garcia AA, Sui XD, Siegel RD, Slomovitz BM, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I. JCO Precis Oncol. 2022 02; 6:e2100424.
-
Levandowski CB, Jones T, Gruca M, Ramamoorthy S, Dowell RD, Taatjes DJ. The ?40p53 isoform inhibits p53-dependent eRNA transcription and enables regulation by signal-specific transcription factors during p53 activation. PLoS Biol. 2021 08; 19(8):e3001364.
-
Rubin JD, Stanley JT, Sigauke RF, Levandowski CB, Maas ZL, Westfall J, Taatjes DJ, Dowell RD. Transcription factor enrichment analysis (TFEA) quantifies the activity of multiple transcription factors from a single experiment. Commun Biol. 2021 06 02; 4(1):661.
-
Moroney MR, Woodruff E, Qamar L, Bradford AP, Wolsky R, Bitler BG, Corr BR. Inhibiting Wnt/beta-catenin in CTNNB1-mutated endometrial cancer. Mol Carcinog. 2021 08; 60(8):511-523.
-
Raj N, McEachin ZT, Harousseau W, Zhou Y, Zhang F, Merritt-Garza ME, Taliaferro JM, Kalinowska M, Marro SG, Hales CM, Berry-Kravis E, Wolf-Ochoa MW, Martinez-Cerdeño V, Wernig M, Chen L, Klann E, Warren ST, Jin P, Wen Z, Bassell GJ. Cell-type-specific profiling of human cellular models of fragile X syndrome reveal PI3K-dependent defects in translation and neurogenesis. Cell Rep. 2021 04 13; 35(2):108991.
-
Hicks HM, McKenna LR, Espinoza VL, Pozdeyev N, Pike LA, Sams SB, LaBarbera D, Reigan P, Raeburn CD, E Schweppe R. Inhibition of BRAF and ERK1/2 has synergistic effects on thyroid cancer growth in vitro and in vivo. Mol Carcinog. 2021 03; 60(3):201-212.
-
Kondapalli L, Worth S, Hawi R, Vachhani P, Arora G, Bhatia R, Lenneman CG. Collaborative cardiovascular management of patients with chronic myeloid leukemia on tyrosine kinase inhibitors. Vasc Med. 2020 06; 25(3):246-254.
-
Rizzotto D, Zaccara S, Rossi A, Galbraith MD, Andrysik Z, Pandey A, Sullivan KD, Quattrone A, Espinosa JM, Dassi E, Inga A. Nutlin-Induced Apoptosis Is Specified by a Translation Program Regulated by PCBP2 and DHX30. Cell Rep. 2020 03 31; 30(13):4355-4369.e6.
-
Danilov AV, Herbaux C, Walter HS, Hillmen P, Rule SA, Kio EA, Karlin L, Dyer MJS, Mitra SS, Yi PC, Humeniuk R, Huang X, Zhou Z, Bhargava P, Jürgensmeier JM, Fegan CD. Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia. Clin Cancer Res. 2020 06 15; 26(12):2810-2818.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|